Effects of Cacao Flavonoids in Long COVID-19 Patients with Chronic Fatigue (FLALOC)
| Registry | NCT06064838, acronym FLALOC |
|---|---|
| Status | Completed |
| Phase | Not applicable |
| Study type | Interventional; randomized, parallel, masking: triple, treatment |
| Enrollment | 46 (Actual) |
| Sponsor | Guillermo Ceballos Reyes (Other); collaborators: Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado |
| Conditions | Long Covid19, Fatigue Syndrome, Chronic |
| Interventions | Flavonoids (Dietary supplement) |
| Dates | start 2023-08-01, primary completion 2024-08-01, completion 2024-09-30, first posted 2023-10-03, last updated 2024-10-01 |
| Locations | 1 site in Mexico |
Related Papers Related Patents Related Grants Related Experts
All trials for Long Covid19 All trials for Fatigue Syndrome, Chronic All trials of Flavonoids
The study use a triple blind, placebo-controlled design enrolling male and female subjects between 30-70 yo to evaluate the effect of daily consumption of a cacao supplement on inflammation, endothelial damage, handgrip strength, fatigue scale and quality of life.
The study use a triple blind, placebo-controlled design enrolling male and female subjects between 30-70 yo distributed homogeneously at random in two groups: the control group (Placebo) and the intervention group (Cacao Flavonoids) both groups affected for 90 days.
The variables to consider will be: Interleukins (IL-1b, IL-6), Tumoral Necrosis Factor alpha (TNF-α) and syndecan-1.
For physical performance is evaluated the handgrip strength. The investigators also assessed quality of life using the Health Related QoL (EQ-5D) questionnaire, and the numerical fatigue rating scale.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Flavonoids | Experimental | Dietary Supplement: Flavonoids | Capsules with 500mg of cacao flavonoids, twice a day for 90 days |
| Placebo | Placebo comparator | Dietary Supplement: Flavonoids | Capsules with 500mg of excipients, twice a day for 90 days |
Sex: All, ages: 30 Years to 70 Years
Inclusion Criteria: * Post-COVID-19 patients, at least 6 months after symptom onset * Chronic fatigue Exclusion Criteria: * Allergy or intolerance caused by active ingredients * Pregnancy or lactation * BMI >35 * chronic liver disease * chronic kidney disease
| Facility | City | Country | Status |
|---|---|---|---|
| C.E. Indianilla | Mexico City, Mexico City | Mexico |